• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Reimbursement Connection®
  • NCD Overview

  • Overview
  • Amgen™ Oncology Assistance
  • Aranesp®
    (darbepoetin alfa)
  • Neulasta®
    (pegfilgrastim)
  • NEUPOGEN®
    (Filgrastim)
  • EPOGEN®
    (Epoetin alfa)
  • Sensipar®
    (cinacalcet)
  • Enbrel®
    (etanercept)
  • Kepivance®
    (palifermin)
  • Kineret®
    (anakinra)
  • Vectibix®
    (panitumumab)
National Coverage Determination

Please find the latest updates below:

Revised ESA NCD Article Posted to MLN Matters
Change Request 5818
CMS ESA draft NCD
CMS press release
NCD: Full document from CMS
Amgen press release
footer